Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.

Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.

Item

http://www.wikidata.org/entity/Q47744458

Q47744458

about

Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.

Item

http://www.wikidata.org/entity/Q47744458

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Progression-Free Survival in P ...... n Community Oncology Settings.

@en

Progression-Free Survival in Patients Receiving Chemotherapy Alone

@nl

type

Item

label

Progression-Free Survival in P ...... n Community Oncology Settings.

@en

Progression-Free Survival in Patients Receiving Chemotherapy Alone

@nl

prefLabel

Progression-Free Survival in P ...... n Community Oncology Settings.

@en

Progression-Free Survival in Patients Receiving Chemotherapy Alone

@nl

P1476

Progression-Free Survival in P ...... n Community Oncology Settings.

@en

P2093

Arthur C Houts

http://www.w3.org/2001/XMLSchema#string

Joleen M Hubbard

http://www.w3.org/2001/XMLSchema#string

Mark S Walker

http://www.w3.org/2001/XMLSchema#string

Nicolas Sommer

http://www.w3.org/2001/XMLSchema#string

Sacha Satram-Hoang

http://www.w3.org/2001/XMLSchema#string

Sarika Ogale

http://www.w3.org/2001/XMLSchema#string

Yousuf Zafar

http://www.w3.org/2001/XMLSchema#string

P2860

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.

P2888

s12029-017-0017-8

P31

scholarly article

P356

10.1007/S12029-017-0017-8

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29058260

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.

about

Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698

P921